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ABSTRACT 
The discovery of the bacterium Helicobacter pylori by the Aus- 
tralians Warren and Marshall in 1982 has revolutionized the 
management of gastroduodenal diseases. Antimicrobial ther- 
apy is now an essential component of the treatment of all duo- 
denal ulcers and most gastric ulcers. A causal role in gastric 
adenocarcinoma and low-grade B-cell gastric lymphomas has 
resulted in the investigation of strategies for large scale elimi- 
nation of H. pylori from certain populations. However, interest 
in this fascinating bacterium amongst microbiologists in gen- 
eral, and infectious disease researchers and clinicians through- 
out the world in particular, has tended to be lukewarm. 
Helicobacter pylori diseases are not considered a priority in the 
developing world and are viewed as infections for which treat- 
ment is a luxury that can be afforded only by developed soci- 
eties. A thesis of this article is that mass impacts of this 
ubiquitous pathogen on the developing world may be more 
than is thought and that, in the long term, intervention may be 
desirable as long as it can be made simple and cheap. 
Progress in Helicobacter research has come such a long way 
in the past 10 years that immunization may now be an attain- 
able goal. 
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Peptic ulcer: “An ulceration of the mucous membrane of 
the stomach or duodenum - occurs when aggressive 
factors such as acid and pepsin overwhelm the normal 
defensive properties inherent in the mucosa.“’ Such was 
the conventional wisdom about a disease estimated to 
have a lifetime prevalence of 5 to lo%, thus afflicting 
more than 100 million persons throughout the world. 
Ulcer treatments were totally designed to induce acid 
suppression and were considered successful. All this 
changed when Robin Warren, a histopathologist in Perth, 
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Western Australia, followed up his observation of an asso- 
ciation between a spiral-shaped bacterium and histologic 
gastritis.* Others had seen bacteria in the stomach, but 
none previously had suggested causality.3 Warren con- 
vinced Barry Marshall, a young internist, that the organ- 
ism was worth culturing, and so Helicobacterpylori was 
born in 1982.* The details of the discovery are found 
elsewhere.5 What is worth emphasizing is the almost uni- 
versal scepticism with which the discovery was greeted. 
Gastroenterologists had always assumed gastric juice was 
sterile and knew little about the bacteria. Bacteriologists 
could not distinguish body from antrum, and so, few 
were interested. Even today, despite overwhelming evi- 
dence, commentaries are still being published in influ- 
ential journals suggesting “medical practitioners should 
keep an open mind until the crucial experiments have 
been done.“6 This biased and poorly researched view- 
point induced a rapid response of letters illustrating how 
the tide has turned in favor of the role of this organism 
in peptic ulcer.’ The literature has exploded in recent 
years, and even the most ardent sceptics have joined the 
“mlori band wagon.” This is for good reason. The evi- 
dence for this helical-shaped gastric bacterium being a 
major pathogen is now so complete that two relatively 
conservative bodies have been prepared to make some 
far-reaching conclusions. Thus, a Consensus Develop- 
ment Panel of the National Institutes of Health (NIH) in 
the United States concluded that the evidence for H. 
pylori as a gastroduodenal pathogen was strong enough 
to recommend that all ulcer patients with H.pyZori infec- 
tion be given antimicrobial agents as well as antisecretory 
drugs.8 Likewise, a working group on the “Evaluation of 
Carcinogenic Risks to Humans~ of the World Health Orga- 
nization’s (WHO) International Agency for Research on 
Cancer (IARC), concluded, “Infection with Helicobacter 
pylori is carcinogenic to humans” and graded it a group 1 
carcinogen, the same category as the hepatitis B virus.9 
Interest in H.pyZori among microbiologists in general, 
and infectious disease researchers and clinicians through- 
out the world in particular, has tended to be lukewarm 
as evidenced by the scientific programs of national and 
international meetings. H. pylori diseases are not con- 
sidered a priority in the developing world and are viewed 
as infections for which treatment is a luxury that can be 
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afforded only by developed societies. A thesis of this arti- 
cle is that mass impacts of this ubiquitous pathogen on 
the developing world may be more than is thought and 
that, in the long term, intervention may be desirable as 
long as it can be made simple and cheap. Progress in 
Helicobacter research has come such a long way in the 
past 10 years that immunization may now be an attain- 
able goal. 
HELICOBACTER PYLORI-THE BACTERIUM 
Helicobacter pylori is a microaerophilic gram-negative 
helical-shaped bacterium that has adapted over the period 
of evolution of its human host to survive in the hostile 
gastric environment. lo Other animals have their own gas- 
tric bacteria; many have now been cultured following the 
initial discovery of H.pyZori.” All these bacteria also have 
been found to belong to the genus Helicobacter, thus 
the ferret has Helicobacter musteZae,‘2 the cat HeZi- 
cobacter felis, l3 and even the cheetah has its own heli- 
cobacter, Helicobacter acinonyx.14 In more recent years, 
the genus has expanded further to include a number of 
Helicobacter spp that normally inhabit the lower bowel 
of birds and other animals.15 With the announcement of 
the isolation of Helicobacter bilis from rodents, the num- 
ber of species stands at 13, with more in the wings.” A 
pathogenic role for some of these bacteria has been sug- 
gested in cheetahs and cats,17x1* whereas Helicobacter 
hepaticus, a lower bowel colonizer of rodents is associ- 
ated with hepatoma and hepatocellular carcinoma.‘9 
The distinctive features of the gastric helicobacters, 
in particular H.pylori, that allow colonization of the gas- 
tric mucosa are a specialized motility that allows the bac- 
teria to swim down to the surface,20 a remarkably active 
urea enzyme that allows survival in gastric acidity,21 and 
specific tissue adhesions that allow a proportion of the 
H. pylori to adhere to gastric-type ti.ssue.22~23 However, 
the natural niche of the gastric helicobacters is the gas- 
tric mucus, this is the niche to which the bacteria have 
evolved.24 
HELICOBACTER PYLORI-THE DISEASES 
Following ingestion of H. pylori, there is a brief period 
of symptomatic disease that correlates with active gas- 
tritis, with infiltration of large numbers of polymor- 
phonuclear leukocytes into the gastric mucosa. 
Symptoms include cramping epigastric pain, vomiting, 
nausea, and flatulence. This syndrome has been noted 
in two heroic self-administration experiments and a num- 
ber of cases in which the H.pyZori has been contracted 
by endoscope.25-27 The reality is that if such episodes of 
a natural primary infection are common they would be 
missed, as such individuals would never be endoscoped. 
The most common H.pyZori infection is a symptom-free 
chronic histologic gastritis with persistent activity (i.e., 
presence of polymorphonuclear leukocytes) (so called 
active/chronic or type B gastritis).28 This is further evi- 
dence of a highly evolved host-parasite relationship. In 
some cases, this H.pyZori infection can progress to a duo- 
denal ulcer, In these patients, the bacterium colonizes 
small islets of gastric-type tissue (gastric metaplasia) in the 
duodenal bulb and sets up a duodenitis that is the focus 
for the weakening in the mucosa, which becomes the 
ulcer2’ Although such ulcers heal rapidly with acid-sup- 
pressive therapy, the majority recur within 1 year. If the 
H. pylori infection is cured with effective antimicrobial 
therapy, then the ulcers do not come back. This is the 
conclusive evidence as to H.pyZori as a cause of duode- 
nal ulceration, and it no longer can be argued away. 
Thus, Labenz selected a group of 190 patients with recur- 
rent ulcers and followed them for 1 to 4 years after cure 
of H.&yZori infection. 29 Pre- and post-therapeutic courses 
were examined. The l-year ulcer recurrence rate 
decreased from 68% to 1 . l%, and the second year relapse 
rate dropped from 91% to 3%. 
Whereas up to 95% of duodenal ulcers are caused 
by H. pylori, there are a number of gastric ulcers (i.e., 
ulcers in the stomach) that are caused by other agents 
(e.g., non-steroidal anti-inflammatory agents [NSAIDS]). 
However, the study by Labenz and Borsch included 59 
gastric ulcers, as have other H.pyZori treatment studies, 
and again, major reductions in relapse were observed 
when H.pyZori infection was cured.29 Thus 60 to 80% of 
gastric ulcers also are probably caused by H. pylori, 
although this will vary from country to country depend- 
ing on NSAID use. 
Most H.pyZori infections are acquired in childhood. 
Given the infection remains for life and continually 
induces a chronic inflammatory response, it is not sur- 
prising that long-term consequences are found. This is 
the logic behind the suggestion of H.pylori infection as 
an essential precursor lesion, hence, cause of gastric can- 
cer. Current hypotheses suggest that either the increased 
cell turnover induced by H.pyZori infection itself or severe 
atrophic gastritis resulting from long-term H.pyZori-caused 
inflammation leads to hypochlorhydria. These mucosal 
changes in association with dietary factors such as high 
salt and low vitamin C, render the gastric mucosa more 
susceptible to spontaneous or carcinogen-induced DNA 
damage, resulting in tumor induction.9 The evidence is 
epidemiologic. In three well-controlled prospective stud- 
ies, H.pyZori infection status was assessed in the sera of 
gastric cancer patients and matched controls who had 
been studied for many years prior to the development of 
the tumor.30-32 Significant odd ratios ranging from 2.6 to 
6.0 were obtained. For example, Nomura et al compared 
109 patients with gastric carcinoma with 109 age-matched 
contro1s;30 H. pylori positivity was assayed by serology. 
The serum was from men taking part in a cohort study 
in which 7478 Japanese-Americans living in Hawaii 
provided blood between 1967 and 1970 as part of a 
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population study of heart disease. The cancers were diag- 
nosed between 1968 and 1989. Ninety-four percent of 
the cancer patients had antibodies to H.pyZori, compared 
to 76% of controls. This resulted in an odds ratio of 6.0 
(95% CI: 2.1- 17). Given the high background prevalence 
of H. pylori infection in the groups being studied, as 
shown by the prevalence in the control group, and the 
likely multifactorial nature of gastric cancer, these data 
were remarkable and good enough to convince the WHO 
L4RC panel. Furthermore, the results of a recent study on 
younger Japanese cancer patients, in whom the back- 
ground H.pyZori infection prevalence is much lower than 
in the older populations, has completely justified the judg- 
ment of the IARC group. Kikuchi and colleagues assayed 
for H. pylori infection in 105 hospitalized gastric cancer 
patients and appropriate controls.33 In cancer patients, 
evidence of H.pylori infection was high, ranging from 83 
to 93%, whereas in controls 35 to 44% were infected. 
These figures produce odds ratios from 5 to 36, depend- 
ing on the age group looked at, with stronger relation- 
ships at the younger ages. These remarkable results 
strongly support causality Other, seemingly negative, stud- 
ies in which serology is performed on older gastric can- 
cer patients and that challenge the H. pylori cancer 
hypothesis, could be explained by the fact that as the 
damage increases in an atrophic stomach the gastric envi- 
ronment changes, the ecologic niches disappear, and infec- 
tion is lost, resulting in decline in serologic responses.9 
A less common gastric tumor that appears to be 
more prevalent in some communities (e.g., Southern 
Switzerland and Northern Italy) is primary low-grade B- 
cell gastric lymphoma, also called low-grade MALT lym- 
phoma.34 The association with H. pyZori infection with 
these lesions is 95 to 1OO%.35 It is now generally assumed 
the H.pyZori induces an immune response in all infected 
persons with induction of lymphoid follicles.36 Over a 
long period, presumably triggered by continued antigenic 
challenge, some of these follicles develop into a prema- 
lignant state, the low-grade lymphoma. This lesion has 
the potential to further develop into invasive high-grade 
tumors with serious consequences.35 In the low-grade 
lymphomas, cure of H.pyZori removes the antigenic load, 
and the lymphomas often regress.37-39 
HELICOBACTER PYXORI INFECTION-DIAGNOSIS 
Infection with this gastric pathogen can now be diag- 
nosed reliably by either invasive or non-invasive meth- 
ods.*O At endoscopy, biopsies can be processed in many 
ways to show presence of the bacterium. Infected biop- 
sies placed in commercial or “in-house” urea reagent 
rapidly give a color change, usually red, due to the pres- 
ence of large amounts of the enzyme urease.41,42 The 
biopsy can be homogenized, placed on a range of culture 
media, and simply grown, providing plates are kept moist, 
a good microaerophilic atmosphere is maintained, and 
incubation is for long enough (e.g., 4 days). Finally, and 
possibly the gold standard for diagnosis, is examination by 
an experienced histopathologist of sections of formalin- 
f=ed biopsies where the bacterium, with its classic shape, 
easily can be seen and the grade of pathology estimated 
(Figure 1).43 Multiple biopsies of both antrum and body 
increase the likelihood of a positive diagnosis in infected 
patients. A non-invasive test, that also depends on the 
high activity of the H. pylori urea enzyme, is the urea 
breath test. Patients swallow a sample of urea labeled with 
either Cl* or C13.44,45 If the patient is infected, the H.pyZori 
m-ease breaks down the ingested urea, and either ‘*CO, 
or 13C0, is exhaled in the breath. This labeled carbon 
dioxide is obtained by blowing with a straw into a trans- 
port balloon or solution. The labeled gas in the speci- 
men is then detected by either a scintillation counter (13C) 
or a mass spectrophotometer (‘*C). These tests are 
becoming readily available in many countries and are par- 
ticularly appropriate for follow-up treatment.46 
For epidemiologic studies, serology is the diagnostic 
test of choice.” Owing to the levels of antibody generated 
during infection, high cutoffs can be used for enzyme- 
linked immunosorbent assay (ELISA) tests, and so the tests 
are reliably diagnostic of active infection. There are many 
successful commercial kits on the market, or “in-house 
tests” are available. It is important that any test be vali- 
dated for the population under study.48 Serology is not 
yet well validated for follow-up therapy, because of the 
time taken for antibody levels to drop below the diag- 
nostic cutoff (i.e., 6-12 mo). A consequence of the avail- 
ability of so many good serologic kits is a pressure to use 
them in the diagnosis of any dyspeptic patient. This poses 
a problem as one tries to interpret the relevance of a pos- 
itive result. In some communities and in age groups likely 
to suffer dyspepsia, more than 50% of persons will be 
infected and so will give a positive serologic test. How- 
ever, serology does not predict symptoms (i.e., asympto- 
matic and duodenal ulcer patients will both be positive). 
Likewise, the evidence of H.pyZori as a cause of non-ulcer 
dyspepsia is very weak. However, many dyspeptics will be 
H.pyZori positive. Some claim that serology will reduce 
the number of endoscopies done if only positives are 
endoscoped, but this is controversiaI.49 The infectious 
disease physician needs to be clear as to the significance 
of the diagnosis of H.pylori infection. Potentially, H.pylori 
diagnosis could be a stimulus to excessive antibiotic use 
(e.g., clarithromycin, amoxicillin, metronidazole), which 
in itself could have implications with respect to other 
infectious agents. 
HELICOBACTER PYLORI INFECTION- 
EPIDEMIOLOGY 
HeZicobacterpyZori is described as a disease of high preva- 
lence in the developing world and one that is declining 
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Figure 1. Gastric biopsies from patients infected with H. pylori. A, chronic gastritis with activity characterized by large numbers of inflamma- 
tory cells including polymorphonuclear leukocytes (original magnification, X400); B, large numbers of spiral-shaped bacteria ( -) in gastric pits 
(original magnification, Xl 000); and C, a lymphoid follicle (original magnification, X200). 
in developed societies. This simple division could be 
misleading; for example, more than 30% of children were 
found to be infected in Belfast, a city in a developed soci- 
ety, with infection correlating with socioeconomic sta- 
tus.50 Table 1 shows the prevalence of infection in all the 
countries of the world reported to date. Much emotion 
is generated about H.pyZori epidemiology as the mode of 
transmission is debated.51 The likely scenario is as fol- 
lows: most people become infected in childhood, proba- 
bly from their parents or a sibling. There is a clear 
association with socioeconomic status, with density of liv- 
ing, in particular number per room, being a major cor- 
relate. Transmission is person to person, probably mainly 
oral/oral via refluxed gastric secretion; however, fecal/oral 
spread probably occurs and there is a possibility that in 
early infection there is greater excretion via feces. There 
is increasing evidence to suggest that some children may 
lose their H.pyZori infection only to become reinfected 
at a later stage. 52 After early childhood, the infection is 
usually established for life. The apparent increasing 
prevalence of H.&yZori infection with age is, in part, due 
to a cohort phenomenon; that is, due to living standards 
improving, fewer children aged 5, for example, are 
infected than were infected 20, 30, 40, 50 years ago.53,54 
Helicobacter pylori infection past childhood is probably 
relatively hard to contract. In an African population with 
a reasonably high prevalence, re-infection following cure 
of infection was very low. This is probably due to lack 
of exposure as a person ages rather than immunologic 
protection as a result of prior infection.55 An exception 
with respect to adults is the gastroenterologists them- 
selves. There is good evidence that their high exposure 
to gastric secretions in the pre-glove era resulted in infec- 
tion.56,57 If carried out correctly, normal disinfection 
procedures are adequate to rid the endoscope of the 
bacterium. 58 
The reservoir of infection of H.pyZori is the human. 
In about 1% of gastritis cases, patients are infected with 
the related bacterium Helicobacter heilmannii, which 
is known to colonize a range of animals, such as cats, 
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Table 1. Seroepidemiology of Helicobacterpylori Infection peace will ensure H.pylori will be with us for many years 
Percentage of Population 
Repotted Positive for H. pylori 
to come. 
Country a-1 0 Years of Age 40-50 Years of Age 
Algeria 45 96 
Australia 4 34 
Belgium - 54 
Brazil 27 - 
China 23 65 
Denmark - 30 
Estonia - a7 
Finland 90 
France 3 32 
Gambia 31 - 
Germany 69 
Greece - 75 
Iceland - 59 
India 60 - 
Italy 48 
Italy (San Marino) - 60 
Ivory Coast 55 78 
Japan - 86 
Nigeria 50 - 
Papua/New Guinea 35 75 
Peru 42 73 
Poland 18 94 
Portugal 69 
Saudi Arabia 40 80 
Slovenia 70 
Thailand 10 90 
United Kingdom 5 41 
United States 5 50 
Vietnam 13 86 
Zaire 79 a7 
Note: This is approximate data compiled from all the available literature. 
Acknowledgment of all sources was impractical, but a listing is available 
from the author if needed. 
dogs, and pigs, indicating that animals can be a rare 
source of infection5” In a recent finding, H.pyZori was 
found in a colony of laboratory cats that had no natural 
feline helicobacters and presumably contracted the bac- 
terium from a human handler.60 From this work it has 
been suggested that cats are a reservoir of H.pyZori. How- 
ever, this cat infection was an artificial situation, and 
because the bacterium has yet to be found in domestic 
cats, it is too premature to place the animal in the trans- 
mission cycle. 
Helicobacterpylori is being lost from the developed 
world as is the duodenal ulcet61 This natural loss of the 
bacterium correlates with improvement in living 
conditions and socioeconomic status. This organism 
evolved its natural mode of transmission centuries ago 
when there was no “developed world.” Relying on close 
contact, it did not acquire bile resistance, and fecal spread 
was minimal, because most bacteria were killed in the 
upper bowel. As people spread apart in their comfortable 
homes, H. pylori was deprived of its natural pathways 
from person to person. Children do not get infected and 
so the bacterium is lost. However, as health and hygiene 
infrastructure are lost in many countries in this turbulent 
world, the organism is likely to return. The inequality of 
life on this planet and our seeming inability to live in 
HBLICOBACTER PYLORI--PATHOGENESIS 
Explanations as to how H.pylori causes diseases with a 
symptomatic outcome remain surprisingly unsatisfactory 
As described above, colonization is reasonably well under- 
stood. A significant focus has been to understand how H. 
pylori causes ulcers. Thus much energy has been devoted 
to measuring effects of the organism on the layers that 
protect the stomach from gastric acid. It is claimed that 
significant in vitro effects on mucus are a result of enzy- 
mic action weakening the layer and reducing viscosity, 
although other researchers have argued that this does not 
occur in viva.@ Certain strains of H.pyZori produce a vac- 
uolating cytotoxin that damages tissue culture cells in 
vitro.63,64 The underlying lesion of all infections is inflam- 
mation, and more is being learned about this. Bacterial 
products are released into gastric mucosa and attract neu- 
trophils and monocytes to the site.65,66 Polymorphonu- 
clear leukocytes release toxic products into the tissue 
on contact with H. pyZori.67 Gastric mucosa releases 
cytokines, such as interleukin (IL)-& into gastric tissue, 
recruiting more inflammatory cells.68-70 As a vigorous 
immune response is induced, so certain lymphocyte pop- 
ulations (CD4, CD& CD22) increase in numbers.‘l Acti- 
vation of the antigen transporting endocytic-endosomal 
system and de novo expression of antigen-presenting 
human leukocyte antigen HLA-DR molecules are evidence 
of intense immune activity. Fiocca and colleagues con- 
clude that both bacterial cytotoxicity and inflammatory 
cell aggression against gastric mucosae may predispose 
the patient to ulcer disease. ‘l However, the above expla- 
nations are clearly not enough, because the vast majority 
of H.pyZori infected persons do not get ulcers. Some have 
argued in favor of super strains of H. @ori, the ulcero- 
genie strain;72 however, to H. pylori, production of an 
ulcer is of no consequence, the bacterium certainly did 
not evolve to produce ulcers, and so host factors are likely 
to be most important.73 To some extent both scenarios are 
probably true. Much has recently been written about cagA 
positive and negative strains. The gene cagA is co- 
expressed with the vacuolating cytotoxin (hence gyto- 
toxin associated gene) and is found in strains with an 
increased capacity to induce severe disease.74,75 Thus, a 
greater proportion of patients with ulcer disease and gas- 
tric cancer are cagA positive although negative strains 
can cause the disease.69z76 The gene appears to be a marker 
for an ability to induce a more severe inflammation and 
positive strains do induce more of the inflammatory cyto- 
toxin IL-S in vitro and in vivo.70,77 On the host side there 
does appear to be some link with immunoreactivity, with 
the HLA-dqal being reported to make a contribution to 
the host response against H.pylori.78 
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At present, the best hypothesis to explain the patho- 
genesis of all the disease modalities is that the key factor 
is the intensity of the inflammatory response that is 
increased with cagA positive strains and influenced by 
host immunoresponsiveness and the location of the 
inflammatory reaction. Certain anatomic regions have a 
structure that is more susceptible to damage (e.g., the 
junction of body and antrum in the stomach and gastric 
metaplasia in the duodenum) due to architectural anom- 
alies and such other factors as lessened blood flow. If 
the inflammatory threshold is exceeded and the acid level 
is high enough, a small region of mucosa is damaged.79,s0 
This site becomes the focus for further acid damage, and 
an ulcer results. If certain dietary factors are present (e.g., 
high salt diet) to potentiate increased cell turnover and 
low vitamin C, increasing the presence of tissue-reactive 
oxygen radicals, then those persons with the high inflam- 
matory profile will have the most severe long-term gas- 
tric damage and will be more likely to develop gastric 
cancetsl 
There can be no easy explanation of peptic ulcer or 
gastric cancer. They are multifactorial diseases depen- 
dent on acid output, diet, genetic susceptibility, immune 
reactivity, and the strain of H.pyZori. However, the essen- 
tial prerequisite is the infection. Remove the bacterium, 
and you cure or prevent the disease. What are the treat- 
ment options? 
HELICOBACTER PYZORI INFECTION- 
TREATMENT 
The driving force in the quest for an effective anti-H.BZori 
therapy has been the realization that if the infection is 
cured, the ulcer is cured. Yet treatment has proved 
extremely difficult. HeZicobacterpyZori is sensitive to the 
great majority of antibiotics in vitro, yet these agents do 
not work as a monotherapy in vivo. Initial clearance of 
infection could be achieved but, with all monotherapies, 
when biopsies were taken 1 month after treatment, the 
bacterium had returned. Given the ecologic niche of H. 
pylori in gastric mucus, it requires a more concentrated 
attack to remove it from the stomach. The first effective 
therapies were triple regimens of a bismuth salt, either 
colloidal bismuth subcitrate or subsalicylate (120 mg four 
times daily), metronidazole (400 mg three times daily) and 
either tetracycline or amoxicillin (500 mg four times 
daily).82,83 With good patient compliance, 2-week or even 
l-week treatment, these regimens consistently achieve a 
90% cure of infection.84~85 However, compliance is an issue. 
Not only are large numbers of tablets required (e.g., 11 
per day), but there are annoying side effects, which though 
not dangerous, encourage non-compliance (e.g., metallic 
taste of the imidazole, blackening of the tongue and stool, 
and nausea). So alternatives have been sought. The acid- 
suppressive drug omeprazole that inactivates the acid- 
secreting proton pump of the parietal cell, effectively 
heals ulcer with little effect on H,pyZori infection. How- 
ever, addition of amoxicillin to the treatment results in 
significant cure of H. pylori infection. This synergistic 
effect is thought to be due to reduction of acid destruc- 
tion of the antibiotic and effects on the ecology of the bac- 
terium. Using high-dose amoxicillin (750 mg three times 
daily) and omeprazole (40 mg three times daily) for 2 
weeks, 91% cure rates have been achieved.86 However, 
this is an expensive regimen. Lower doses of this dual 
therapy have been extensively studied, and results have 
varied.85 The current fashion now for those who wish an 
alternative from the classic triple therapy is another triple 
regimen that preserves the synergistic effect of a protein 
pump inhibitor, retains an imidazole (e.g., metronidazole 
or tinidazole), and includes clarithromycin, a macrolide 
antibiotic that has excellent H.pyZori activity A l-week 
treatment of 20 mg omeprazole (once per day), 250 mg 
clarithromycin (twice daily), and 500 mg tinidazole (twice 
daily) achieved a cure rate of 95%.87 A major multicenter 
trial with similar regimens just reported also achieved a 
more than 90% cure.88 Other protein pump inhibitors and 
acid suppressants, such as ranitidine are beginning to 
show similar results.89 And so the classic bismuth triple 
therapies or the newer acid-suppression therapies are now 
treatments that should be used for all H.pyZori positive 
peptic ulcer patients as per the NIH guidelines8 Antimi- 
crobial treatment for non-ulcer dyspepsia patients or as a 
prophylaxis for gastric cancer is not yet warranted on a 
large scale. 
The only other indication for anti-H. pylon therapy 
is in the small number of patients diagnosed with low- 
grade B-cell lymphomas. This is becoming a regular part 
of this type of lymphoma management, although close 
monitoring of patients is required because elimination 
of the antigenic stimulation of H.pyZori does not affect 
the progression of tumors that have converted to high- 
grade malignancies.39,90 
Whereas effective therapies are now available, clearly 
they are not appropriate for large scale prophylaxis of dis 
ease, and there is a concern that H. pylori has already 
developed resistance to the imidazoles and clarithromycin, 
the essential components of the recommended triple 
therapies. What is required is the only strategy known 
to impact globally on an infectious disease, namely 
immunization. Given the ability of H. pylon to survive 
in a host for a lifetime, despite the active cellular and 
humoral immune responses described above, there has 
been serious doubt about whether a vaccine could be 
developed. 
HELICOBACTER PYLORI IMMUNIZATION- 
KEY TO GLOBAL ERADICATION 
Animal models of H.pyZori infection, an essential to vac- 
cine development, were limited in the early days of H. 
PyZori research, because the bacterium appeared to have 
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a limited host range and would only infect primates, germ- 
free piglets, and germ-free dogsgl Culture of H. feZis, a 
close relative of H.pyZori, allowed the development of a 
convenient small-animal model and so opened up the way 
for vaccine research.92 Helicobacterfelis infects mice and 
in certain mouse strains induces active, chronic gastritis, 
atrophic gastritis, and after long periods of infection, low- 
grade B-cell lymphomas.93-95 In the initial vaccine studies, 
mice were immunized with an oral vaccine of H. feZis son- 
icate plus the mucosal adjuvant cholera toxin.96B97 These 
immunized mice were shown to be completely protected 
against oral challenge with living H. felis. Subsequent to 
this, a vaccine comprised of H.pyZori antigens has been 
shown to be protective with either cholera toxin or the 
heat labile toxin of Eschericbia coli as adjuvant.98,99 
Recombinant urease and heat shock protein have been 
used as protective antigens. The most encouraging vaccine 
finding has been that immunizing regimens, similar to 
those described above, actually cure existing infec- 
tion.lOO,lO1 This possibility of a therapeutic vaccine has 
greatly increased commercial interest in the product, and 
at least four major pharmaceutical companies have a vac- 
cine development program. A vaccine will come, but it 
will probably not be available for up to 8 years. The chal- 
lenge for the infectious disease physician is to decide what 
populations should be immunized. 
HELICOBACTER PYZORI AND THE INFECTIOUS 
DISEASE PHYSICIAN - WHO TO IMMUNIZE? 
Given the history of H.pyZori, the treatment of H.pyZori 
infection will never be the primary responsibility of the 
infectious disease specialist, rather it will remain the 
province of the gastroenterologist and the general prac- 
titioner. The infectious disease physician should be well 
briefed in helicobacteriology and be able to make com- 
ment on what are the rational approaches to therapy. 
This is because indiscriminate use of the triple antimi- 
crobial therapies necessary could have impact on their 
practice. If general practitioners chose to treat all patients 
they find positive, or whom they suspect might be 
infected with H. pylori, the resultant massive use of 
metronidazole and clarithromycin would increase the 
likelihood of development of resistance of not only H. 
pylori strains but also other bacteria with potential to 
cause disease, thus limiting the life of these antimicro- 
bials. Immunization will fall within the responsibility of 
the infectious disease specialist, particularly in the devel- 
oping world. 
A working hypothesis for this article is that H.pyZori 
infection puts an undesirable burden to human health 
with a range of consequences more far reaching than pep- 
tic ulcer disease or gastric cancer. The impact is likely to 
have such long-term effects that large scale H. pylori 
immunization may be a greater priority than hitherto 
suspected. Thus, an early phase of H.pyZori infection, 
hypochlorhydria, may last months or even years. What 
consequence is this going to have on populations with 
continuous contact with intestinal pathogens? Some very 
preliminary work suggests a surprising association of H. 
pylori infection with coronary heart disease, with effects 
on blood coagulability being suggested as a cause.“’ 
Long-term infection with such a pathogen with a con- 
tinual production of cytotoxic and inflammatory prod- 
ucts must eventually take its toll, as do so many other 
chronic pathogens. Correlation between H. pylori infec- 
tion and height may simply be a marker for socioeco- 
nomic status, but it could have significance in some 
cases.lo3 The infectious disease physician working in 
countries with high levels of H.pyZori infection should 
be alert to these possible consequences and explore the 
hypotheses. 
CONCLUSION 
Helicobacter pylori infection may be the most common 
infectious disease caused by a single bacterial etiologic 
agent in the world today. An understanding of the ecol- 
ogy, epidemiology, and pathogenesis of this gastroduo- 
denal pathogen, recent developments in treatment, and 
the possibility of an anti-H. pylori vaccine may lead to 
development of rational intervention strategies with the 
potential to impact on diseases of major morbidity and 
mortality and to bring about unexpected overall positive 
consequences on human health. Large scale intervention 
studies, initially with antibiotics and ultimately with the 
oral vaccine, should become a priority of health author- 
ities in countries where gastric cancer is prevalent and 
ulcers have a substantial incidence. 
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